...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug Design, Development and Therapy >Efficacy of atorvastatin on the prevention of contrast-induced acute kidney injury: a meta-analysis
【24h】

Efficacy of atorvastatin on the prevention of contrast-induced acute kidney injury: a meta-analysis

机译：阿托伐他汀预防对比剂诱发的急性肾损伤的疗效：荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Results of studies on the efficacy of atorvastatin pretreatment on reducing the prevalence of contrast-induced acute kidney injury (CIAKI) in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI) have been controversial. Objective: We undertook a meta-analysis to evaluate the efficacy of atorvastatin on contrast-induced nephropathy (CIN) after CAG or PCI. Materials and methods: We undertook a systematic search of electronic databases (PubMed, Embase, and the Cochrane Library) up to June 2017. A meta-analysis was carried out including randomized controlled trials (RCTs) that compared atorvastatin pretreatment with pretreatment with a low-dose statin or placebo for CIAKI prevention in patients undergoing CAG. The main endpoint was CIN prevalence. Results: Nine RCTs were included in our meta-analysis. Atorvastatin pretreatment reduced the prevalence of CIN significantly (odds ratio [OR] 0.46; 95% confidence interval [95% CI] 0.27–0.79; p =0.004). The benefit of high-dose atorvastatin pretreatment was consistent when compared with the control group (OR 0.45; 95% CI 0.21–0.95; p =0.04). Conclusion: At high doses, atorvastatin pretreatment was associated with a significant reduction in the prevalence of CIAKI in patients undergoing CAG. Pretreatment with high-dose atorvastatin could be employed to prevent CIAKI.
机译：背景：阿托伐他汀预处理对降低接受冠状动脉造影（CAG）或经皮冠状动脉介入治疗（PCI）的对比剂诱发的急性肾损伤（CIAKI）患病率的功效的研究结果一直存在争议。目的：我们进行了荟萃分析，以评估阿托伐他汀对CAG或PCI后对比剂诱发的肾病（CIN）的疗效。材料和方法：截至2017年6月，我们对电子数据库（PubMed，Embase和Cochrane图书馆）进行了系统搜索。进行了荟萃分析，包括将阿托伐他汀预处理与低剂量阿托伐他汀预处理进行了比较的随机对照试验（RCT）。剂量的他汀类药物或安慰剂用于预防接受CAG的患者的CIAKI。主要终点是CIN患病率。结果：我们的荟萃分析中包括9个RCT。阿托伐他汀预处理可显着降低CIN的患病率（几率[OR] 0.46; 95％置信区间[95％CI] 0.27-0.79; p = 0.004）。与对照组相比，大剂量阿托伐他汀预处理的益处是一致的（OR 0.45; 95％CI 0.21-0.95; p = 0.04）。结论：大剂量阿托伐他汀预处理可显着降低接受CAG的患者CIAKI的患病率。大剂量阿托伐他汀的预处理可用于预防CIAKI。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号